Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 2Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Breast 1

Conditions

Multiple Chronic Conditions 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 49fludarabine phosphate 42fludarabine 37Azacitidine 35Busulfan 30Whole-Body Irradiation 26Imatinib Mesylate 24Antilymphocyte Serum 24Tacrolimus 23Mycophenolic Acid 22Cytarabine 21Filgrastim 20Peripheral Blood Stem Cell Transplantation 17Methotrexate 17Melphalan 17Cyclosporine 16venetoclax 14thymoglobulin 14Granulocyte Colony-Stimulating Factor 14Thiotepa 12ruxolitinib 11Stem Cell Transplantation 11Decitabine 11Dasatinib 11Alemtuzumab 11nilotinib 10Radiotherapy 10Rituximab 9Cord Blood Stem Cell Transplantation 9ponatinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Patient Reported Outcome Measures × Myeloid × Clear all
NCT04595851 2022-11-22

Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications

University of Michigan Rogel Cancer Center

Phase NA Terminated
6 enrolled
LymphoidMyeloidOther hematologic neoplasmOther neoplasm

Multiple Chronic Conditions, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡